Antiphospholipid antibodies in lymphoma: prevalence and clinical significance.

[1]  T. Barbui,et al.  Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. , 2003, Blood.

[2]  T. Barbui,et al.  Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. , 2003, Blood.

[3]  H. Inoko,et al.  Autoreactive CD4(+) T-cell clones to beta2-glycoprotein I in patients with antiphospholipid syndrome: preferential recognition of the major phospholipid-binding site. , 2001, Blood.

[4]  M. Samama,et al.  The Thrombophilic State in Cancer Patients , 2001, Acta Haematologica.

[5]  M. Levine,et al.  Epidemiology of Thrombosis in Cancer , 2001, Acta Haematologica.

[6]  R. Asherson.  Antiphospholipid antibodies, malignancies and paraproteinemias. , 2000, Journal of autoimmunity.

[7]  D. D'cruz,et al.  Antiphospholipid Syndrome: General Features , 2000 .

[8]  S. Levine,et al.  Clinical approach to antiphospholipid antibodies , 2000 .

[9]  W A Wilson,et al.  International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. , 1999, Arthritis and rheumatism.

[10]  T. Barbui,et al.  The Risk of Thrombosis in Patients with Lupus Anticoagulants Is Predicted by their Specific Coagulation Profile , 1999, Thrombosis and Haemostasis.

[11]  J. Armitage,et al.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Levine,et al.  Induction of anti-phospholipid autoantibodies by beta2-glycoprotein I bound to apoptotic thymocytes. , 1998, Journal of autoimmunity.

[13]  T. Barbui,et al.  Different Anticoagulant and Immunological Properties of Anti-Prothrombin Antibodies in Patients with Antiphospholipid Antibodies , 1997, Thrombosis and Haemostasis.

[14]  T. Barbui,et al.  Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  T. Barbui,et al.  Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. , 1996, The American journal of medicine.

[16]  I. Scharrer,et al.  Criteria for the Diagnosis of Lupus Anticoagulants: An Update , 1995, Thrombosis and Haemostasis.

[17]  C. Biron,et al.  A prospective epidemiological study on the occurrence of antiphospholipid antibody: the Montpellier Antiphospholipid (MAP) Study. , 1994, Haemostasis.

[18]  G. Papa,et al.  Antiphospholipid Antibodies: Prevalence, Clinical Significance and Correlation to Cytokine Levels in Acute Myeloid Leukemia and Non-Hodgkin’s Lymphoma , 1993, Thrombosis and Haemostasis.

[19]  T. Barbui,et al.  Anticoagulant Activity of β2-Glycoprotein I Is Potentiated by a Distinct Subgroup of Anticardiolipin Antibodies , 1992, Thrombosis and Haemostasis.

[20]  J. Armitage,et al.  Prothrombotic hemostatic abnormalities in patients with refractory malignant lymphoma presenting for autologous stem cell transplantation. , 1991, Bone marrow transplantation.

[21]  J. Connors,et al.  MACOP-B chemotherapy for malignant lymphomas and related conditions: 1987 update and additional observations. , 1988, Seminars in hematology.

[22]  S. Shapiro,et al.  The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants. , 1986, Blood.

[23]  H. Kronenberg,et al.  A Sensitive Test Demonstrating Lupus Anticoagulant and its Behavioural Patterns , 1978, British journal of haematology.

[24]  C. Coltman,et al.  Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma , 1976, Cancer.

[25]  G. Bonadonna,et al.  Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP , 1975, Cancer.